Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955988 | 0.83 | MRGPRX1 (0.47) | MRGPRX1 | |
| SCHEMBL10024296 | 0.74 | — | — | |
| SCHEMBL13740900 | 0.74 | TSHR (0.48) | MRGPRX1 | |
| SCHEMBL5955992 | 0.73 | CYP2C9 (0.55) | — | |
| SCHEMBL5955962 | 0.72 | USP2 (0.57) | MRGPRX1PARP10MAPK10 | |
| SCHEMBL8516272 | 0.71 | KDM4E (0.54) | — | |
| SCHEMBL7219476 | 0.70 | MRGPRX1 (0.52) | MRGPRX1 | |
| SCHEMBL9324446 | 0.70 | KDM4E (0.53) | — | |
| SCHEMBL5265644 | 0.69 | MKNK1 (0.51) | MAPK10 | |
| SCHEMBL1076677 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | claimed |
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | SRC, LCK, ABL1 | MRGPRX1 1297/4885PARP10 2046/4885MAPK10 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.